The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Sonnet BioTherapeutics Holdings Inc (NASDAQ: SONN) closed the day trading at $4.03 down -19.72% from the previous closing price of $5.02. In other words, the price has decreased by -$19.72 from its previous closing price. On the day, 0.61 million shares were traded. SONN stock price reached its highest trading level at $4.99 during the session, while it also had its lowest trading level at $3.985.
Ratios:
For a better understanding of SONN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.26 and its Current Ratio is at 0.26.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SONN now has a Market Capitalization of 27514230 and an Enterprise Value of 26967578. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.52. Its current Enterprise Value per Revenue stands at 26.968 whereas that against EBITDA is -1.92.
Stock Price History:
The Beta on a monthly basis for SONN is 1.41, which has changed by 0.19239902 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, SONN has reached a high of $19.30, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is -13.01%, while the 200-Day Moving Average is calculated to be 46.91%.
Shares Statistics:
Over the past 3-months, SONN traded about 902.39K shares per day on average, while over the past 10 days, SONN traded about 577240 shares per day. A total of 7.08M shares are outstanding, with a floating share count of 6.80M. Insiders hold about 3.95% of the company’s shares, while institutions hold 2.70% stake in the company. Shares short for SONN as of 1760486400 were 2184854 with a Short Ratio of 2.42, compared to 1757894400 on 2235520. Therefore, it implies a Short% of Shares Outstanding of 2184854 and a Short% of Float of 32.05.
Earnings Estimates
The stock of Sonnet BioTherapeutics Holdings Inc (SONN) is currently in the spotlight, with 1.0 analysts actively rating and assessing its market standing.
Analysts are recommending an EPS of between -$3.46 and -$3.46 for the fiscal current year, implying an average EPS of -$3.46.
Revenue Estimates
A total of 1 analysts have provided revenue estimates for SONN’s current fiscal year. The highest revenue estimate was $1M, while the lowest revenue estimate was $1M, resulting in an average revenue estimate of $1M. In the same quarter a year ago, actual revenue was $18.63k
